PF-07328948
Sponsors
Pfizer
Conditions
HealthyHealthy AdultsHealthy ParticipantHepatic ImpairmentRenal Impairment
Phase 1
A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants
CompletedNCT05654181
Start: 2022-10-17End: 2023-05-03Updated: 2024-11-05
A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults
CompletedNCT05807490
Start: 2023-04-05End: 2024-07-10Updated: 2024-07-19
A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults
CompletedNCT06837259
Start: 2025-03-19End: 2025-06-11Updated: 2026-02-02
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
RecruitingNCT07269301
Start: 2025-12-22End: 2027-02-23Target: 26Updated: 2026-07-23
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RecruitingNCT07315360
Start: 2026-01-28End: 2027-03-13Target: 28Updated: 2026-05-12
A Study to Learn About How the Body Processes the Study Medicine Called PF-07328948 in Healthy Chinese Adults
CompletedNCT07455240
Start: 2026-03-02End: 2026-04-15Updated: 2026-04-23